{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-26-000019","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2026-08-06T12:03:18+00:00","discovered_at":"2026-08-06T12:05:14.508599+00:00","generated_at":"2026-08-06T12:05:39.340714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novavax Q2 2026 revenue $57M, net loss $53M; raises full-year revenue framework to $235-275M","bullets":["Total revenue $57M (down 76% YoY); net loss $53M vs net income $107M in Q2 2025.","Raised full-year 2026 Adjusted Total Revenue framework to $235-275M (from $230-270M).","Sanofi partnership: Phase 3 CIC trial start triggers $125M milestone; tech transfer completion mid-2027 triggers $75M milestone.","Cash $724M as of June 30, 2026, down from $751M at Dec 31, 2025.","Combined R&D and SG&A expense guidance improved to $370-410M (from $380-420M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-26-000019","json":"https://secwatch.observer/filing/0001000694-26-000019.json","markdown":"https://secwatch.observer/filing/0001000694-26-000019.md","text":"https://secwatch.observer/filing/0001000694-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/0001000694-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069426000019/nvax-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:05:39.340714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}